1. Generics Bulletin
  2. >>Legal & IP

Teva Still Hopes To Reach Deal On US Price-Fixing Allegations

Israeli Firm Remains ‘In Dialog’ With DoJ Over Conspiracy Claims

 
• By Dave Wallace

Teva says it remains hopeful that it can resolve US price-fixing allegations “in a positive way” with the US Department of Justice, but acknowledges that the matter could go all the way to trial.

Signatures
Teva hopes to resolve price-fixing allegations with the DoJ • Source: Shutterstock

Teva says it is still hopeful that it can resolve US price-fixing allegations “in a positive way,” insisting that it remains “in dialog” with the US Department of Justice over wide-ranging allegations that place the Israeli firm at the center of a pricing conspiracy.

The firm was put at the heart of the US investigation into generic price-fixing when a multi-state US lawsuit filed a year ago identified Teva as “a consistent participant in the conspiracies” that also involved numerous other leading industry players

More from Legal & IP

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

More from Generics Bulletin